Ipilimumab is the first CTLA-4 inhibitor approved for melanoma treatment, used in metastatic disease and as an adjuvant for stage III melanoma, enhancing T-cell activity by blocking the interaction between CTLA-4 and B7 molecules, thus promoting the immune system’s attack on tumor cells (30). This evidence concerns the gene CTLA4 and melanoma.